Kaplan’s
Clinical
Hypertension

ypertension continues to increase in preva-
lence both in developed and developing

countries, thereby expanding its role in car-
diovascular and renal morbidity and mortality

worldwide.
Two major developments since the 10th edition
are (1) percutaneous device-based therapy especially
with renal denervation but also carotid baroreceptor
pacing and (2) new hypertension guidelines. The
surge of publications on both topics has raised more
questions than answers and has lead to much debate
among the experts, which stands to confuse clinicians,
patients, and policy makers. What is the future of
device-based therapy, which seemed to hold such
promise for drug-resistant hypertension? What are the
appropriate goals of medication therapy? Do certain
groups of patients deserve more intensive or less
intensive therapy? We have attempted to address these
issues in a fair and balanced manner.
The overall literature about hypertension has

grown, perhaps even more than its increased preva-
lence. A considerable amount of new information is

covered in this edition, presented in a manner that we
hope enables the reader to grasp its significance and
place it in perspective. Almost every page has been
revised, using the same goals as reached in previous
editions.